CN115697323A - 用于治疗骨髓纤维化的化合物 - Google Patents

用于治疗骨髓纤维化的化合物 Download PDF

Info

Publication number
CN115697323A
CN115697323A CN202080094791.2A CN202080094791A CN115697323A CN 115697323 A CN115697323 A CN 115697323A CN 202080094791 A CN202080094791 A CN 202080094791A CN 115697323 A CN115697323 A CN 115697323A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administered
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094791.2A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗西斯·J·希莱斯
安德鲁·马萨尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinesitherapy Co
Original Assignee
Kinesitherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinesitherapy Co filed Critical Kinesitherapy Co
Publication of CN115697323A publication Critical patent/CN115697323A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080094791.2A 2019-12-26 2020-12-23 用于治疗骨髓纤维化的化合物 Pending CN115697323A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
US62/953,654 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
CN115697323A true CN115697323A (zh) 2023-02-03

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094791.2A Pending CN115697323A (zh) 2019-12-26 2020-12-23 用于治疗骨髓纤维化的化合物

Country Status (11)

Country Link
US (1) US20230062278A1 (https=)
EP (1) EP4081213A1 (https=)
JP (1) JP2023508491A (https=)
KR (1) KR20230005808A (https=)
CN (1) CN115697323A (https=)
AU (1) AU2020415440A1 (https=)
BR (1) BR112022012819A2 (https=)
CA (1) CA3166251A1 (https=)
IL (1) IL294369A (https=)
MX (1) MX2022008046A (https=)
WO (1) WO2021133866A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004308A1 (en) * 2006-12-19 2010-01-07 Kozikowski Alan P Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors
US20140135350A1 (en) * 2012-11-15 2014-05-15 Incyte Corporation Sustained-release dosage forms of ruxolitinib
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
WO2019236703A1 (en) * 2018-06-05 2019-12-12 Actuate Therapeutics Inc. Methods of treating malignant lymphoproliferative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004308A1 (en) * 2006-12-19 2010-01-07 Kozikowski Alan P Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors
US20140135350A1 (en) * 2012-11-15 2014-05-15 Incyte Corporation Sustained-release dosage forms of ruxolitinib
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
WO2019236703A1 (en) * 2018-06-05 2019-12-12 Actuate Therapeutics Inc. Methods of treating malignant lymphoproliferative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN JEFFERS 等: "Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis", 《SCIENTIFIC REPORTS》, vol. 9, no. 1, pages 1 - 13 *
TERRA L.等: "9-ING-41, a GSK-3β-selective small molecule inhibitor, in combination with ruxolitinib in JAK2617F primary myelofibrosis", 《CANCER RESEARCH》 *

Also Published As

Publication number Publication date
BR112022012819A2 (pt) 2022-09-06
CA3166251A1 (en) 2021-07-01
IL294369A (en) 2022-08-01
JP2023508491A (ja) 2023-03-02
MX2022008046A (es) 2022-11-14
WO2021133866A1 (en) 2021-07-01
EP4081213A1 (en) 2022-11-02
US20230062278A1 (en) 2023-03-02
AU2020415440A1 (en) 2022-08-04
KR20230005808A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
EP2720696B1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
Ando et al. Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
Loriot et al. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer
EP3755324B1 (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
UA125216C2 (uk) Комбінована терапія
EP3038652B1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
EA028414B1 (ru) Лечение рака ингибиторами tor киназы
JP2013533257A (ja) 血液癌の治療法
JP2024161416A (ja) 骨髄増殖性疾患の治療法
Rui et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis
US20230125429A1 (en) Triptonide or a composition comprising triptonide for use in treating disorders
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
TW201130830A (en) Combined treatment of pancreatic cancer with gemcitabine and masitinib
CN115697323A (zh) 用于治疗骨髓纤维化的化合物
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
Guo et al. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo
JP6143169B2 (ja) 膵臓癌治療剤
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
Haddadin et al. Chemotherapeutic Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230203

WD01 Invention patent application deemed withdrawn after publication